Skip to main content

Peer Review reports

From: Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial

Original Submission
27 Jan 2022 Submitted Original manuscript
26 Feb 2022 Reviewed Reviewer Report - Xiangji Ying
17 Mar 2022 Reviewed Reviewer Report - Ines Rombach
7 Apr 2022 Reviewed Reviewer Report - Ben Thompson
23 May 2022 Author responded Author comments - Dafna D. Gladman
Resubmission - Version 2
23 May 2022 Submitted Manuscript version 2
31 May 2022 Reviewed Reviewer Report - Xiangji Ying
31 May 2022 Reviewed Reviewer Report - Ben Thompson
2 Jun 2022 Reviewed Reviewer Report - Ines Rombach
27 Jun 2022 Author responded Author comments - Dafna D. Gladman
Resubmission - Version 3
27 Jun 2022 Submitted Manuscript version 3
6 Jul 2022 Reviewed Reviewer Report - Ines Rombach
16 Jul 2022 Author responded Author comments - Dafna D. Gladman
Resubmission - Version 4
16 Jul 2022 Submitted Manuscript version 4
20 Jul 2022 Reviewed Reviewer Report - Ines Rombach
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
22 Jul 2022 Editorially accepted
5 Sep 2022 Article published 10.1186/s13063-022-06589-y

You can find further information about peer review here.

Back to article page